What's Hot
View all perspectives
Christian Ammitzbøll RheumTweeter
1 year 4 months ago
Overview of treatment strategies in #Lupus #EULAR2023 #Rheumtwitter https://t.co/zL1nEDajsb
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow’s expanded coverage of the #EULAR2023 meeting is sponsored in part by Bristol Myers Squibb. All content is chosen by RheumNow and its faculty.
Dr. John Cush RheumNow
1 year 4 months ago
RheumNow Eular 2023 Daily Recap Series https://t.co/oZXuyv8wL5
An artificial intelligence model to assess pre-RA hand MRIs has confirmed what human readers have known before: that bone marrow edema and tenosynovitis are objectively the best predictors of future RA development in patients with clinically suspect arthralgias or undifferentiated arthritis.
David Liew drdavidliew
1 year 4 months ago
75 different biosimilars in Europe, and nearly 20 years since the journey started. @EMA_News has led the world on biosimilars #EULAR2023 @RheumNow https://t.co/LFs3FR9dfW
There has been an explosion of trials in SLE, including nonrenal and glomerulonephritis studies. But, what about the JAKis and Tyk2 oral drugs in SLE?
Aurelie Najm AurelieRheumo
1 year 4 months ago
Would you rather have Erosive hands OA or RA?
130+ EHOA and 370+ RA, dis duration > 10 yrs for both cohorts
📍EHOA associated w/ > pain & functional impairment
📍RA associated w/ > comorbidities
@RheumNow #EULAR23 POS0103 https://t.co/KdDG7E6PZw
Aurelie Najm AurelieRheumo
1 year 4 months ago
A model predicts development of PsA in PSO cohort at 1 yr w/ AUC 72.3
Risk factors:
✔️younger age
✔️male
✔️family hx of PSO
✔️back stiffness
✔️nail pitting,
✔️stiffness
✔️PGA
✔️bioDMARDs
5yr prediction model AUC 75
Promising but to be confirmed
@RheumNow #EULAR23 POS0019 https://t.co/boCYOH2sDS
Dr. John Cush RheumNow
1 year 4 months ago
@RheumNow hard at work, shooting KOL videos, at #EULAR2023 https://t.co/C9n2218oeU
Aurelie Najm AurelieRheumo
1 year 4 months ago
ANSWER cohort
Retrospective study 6600+ bio/tsDMARDs ttmt courses, 20 yrs
✔️IL-6Ri is the lowest discontinued for lack of efficacy
✔️CTLA4-Ig is the lowest discontinued due to AEs
✔️Concomitant GC ⬆️30% drug discontinuation due to AEs
@Rheumnow #EULAR23 POS0051 https://t.co/8e6U5KHmX4
Aurelie Najm AurelieRheumo
1 year 4 months ago
The risk of osteoarticular infection following Staph aureus bacteremia is twice higher in RA (1/4) than non RA pop (1/8)
Use of TNFi & orthopedic implants associated w/ OAI risk
Mortality however similar in RA and non RA groups
@RheumNow #EULAR23 POS0033 https://t.co/H6JYkbNu0B
Poster Hall